Cheap Price Ponatinib 99% White Powder from Biocar

Ponatinib is an anticancer drug. It was approved by FDA in December 2012 for the treatment of adult chronic myelogenous leukemia (CML) and "Philadelphia chromosome positive" (PH +) acute lymphoblastic leukemia (ALL). It is mainly used to treat patients who do not respond to dasatinib or nillotinib therapy, or who are unable to tolerate dasatinib or nillotinib, and who are not suitable for subsequent treatment with imatinib. It can also be used to treat patients with a genetic mutation (the "T315I mutation") that makes patients resistant to imatinib, dasatinib, or nilotinib. It is also used to treat CML and pH +ALL in adults who have not been treated with other TKIs. It is currently the only marketed drug that is effective against the BCR-ABL kinase T315I mutation.

Ponatinib was approved in the European Union in July 2013 through a centralised approval process. Panatinib is the third generation of multi-target tyrosine kinase inhibitors. Typical drugs of multi-target tyrosine kinase inhibitors include sunitinib, imatinib, sorafenib and vataranib., for he (Ponatinib) can effectively inhibit the in vitro FGFR1-4 kinase activity, its IC50 alue concentration,2,18 2 and 8 nmol/L respectively, in the absence of interleukin - 3 cells, FGFR1, on behalf of, to curb cells - 4 kinase expression of IC50 alue concentration were 8 August 24 and 34 nmol/L, and tested in each cell, for inhibition of FGFR1-4 phosphorylation, its IC50 alue concentration is 39 29 32 and 39 nmol/L respectively tested on endometrial bladder Stomach and thymus in multiple cell lines FGFR inhibition, relatively, compared with other drugs for showed obvious pharmacological effects, such as its inhibit endometrial AN3CA and MFE - 296 cell proliferation GI50 value of 14 and 61 nmol/L, it shows that, for he is a powerful FGFR inhibitors in mice tumor xenograft model, each day 10 mg/kg or 30 mg/kg, tumor inhibition rate were 49% and 82%, respectively.